- Home
- Publications
- Publication Search
- Publication Details
Title
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 4, Pages e1408747
Publisher
Informa UK Limited
Online
2017-11-29
DOI
10.1080/2162402x.2017.1408747
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy
- (2017) Tzu-Ting Huang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3
- (2017) Chen Qi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1
- (2017) Gang Chen et al. NATURE NEUROSCIENCE
- Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
- (2017) Yelyzaveta Shlyakhtina et al. Cell Death & Disease
- Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo
- (2016) Z. Tao et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer
- (2016) Shisuo Du et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
- (2016) Gregory S. Alexander et al. Journal of Hematology & Oncology
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression Atlas update—an integrated database of gene and protein expression in humans, animals and plants
- (2015) Robert Petryszak et al. NUCLEIC ACIDS RESEARCH
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
- (2015) Jiabei He et al. Scientific Reports
- Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
- (2014) Vassiliki A. Boussiotis et al. CANCER JOURNAL
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells
- (2013) Joanne Y. H. Lim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK
- (2013) Y. Sun et al. MOLECULAR CANCER THERAPEUTICS
- Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations
- (2012) C M Furcht et al. ONCOGENE
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis
- (2012) Shuangwei Li et al. Frontiers of Medicine
- B7-H1 limits the entry of effector CD8+T cells to the memory pool by upregulating Bim
- (2012) Rachel M Gibbons et al. OncoImmunology
- Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1+/CD127− HCV-specific CD8+ cells targeting the virus in chronic hepatitis C virus infection
- (2011) Juan R. Larrubia et al. CELLULAR IMMUNOLOGY
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
- (2010) T. Schatton et al. CANCER RESEARCH
- Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
- (2010) Latanya M. Scott et al. CURRENT PHARMACEUTICAL DESIGN
- SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels
- (2009) Ulrike Lorenz IMMUNOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now